仟源医药(300254) - 2024 Q4 - 年度业绩预告

Financial Performance - The estimated net profit for 2024 is projected to be between 40 million and 52 million CNY, compared to 25.2 million CNY in the same period last year, representing a growth of 58.76% to 106.39%[4] - The net profit after deducting non-recurring gains and losses is expected to be between 22 million and 34 million CNY, a significant increase of 215.74% to 278.88% from a loss of 19 million CNY in the previous year[4] Marketing Strategy - The company has implemented an all-channel marketing strategy, actively expanding into new businesses and markets, resulting in increased revenue compared to the previous year[6] Financial Management - The financial expenses have decreased due to the acquisition of partial equity in Nantong Hengjia, which eliminated the need to accrue financial liabilities from July 2023[7] - The employee stock incentive plan is expected to reduce the net profit attributable to the parent company by approximately 8 million CNY in the second half of 2024[7] - Non-recurring gains and losses are estimated to impact net profit by about 18 million CNY, primarily from asset disposal gains and various government subsidies[7]